According to the 2018 ACC/AHA [26], the 2019 ESC/EAS [27], and the adult treatment panel III (ATP III) cholesterol guidelines [28], LDL-C was considered the major cause of CAD and treated as the primary target for therapy, while other lipids were used as the secondary or supplementary therapeutic targets. This evidence concerns the gene COG2 and coronary artery disorder.